Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Non-Small-Cell Lung

In brief

This study was designed to evaluate the role of canakinumab in combination with docetaxel in subjects with advanced non-small cell lung cancer (NSCLC) previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy.

Key facts

Study ID
NCT03626545
Run by
Novartis Pharmaceuticals
People needed
245
Starts
2019-01-23
Expected to finish
2021-12-20
Last updated by the study team
2023-08-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.